AndroGel 1.62% Boosts BMD in Hypogonadal Osteopenic Men: 24-Month Trial
Reading Time: < 1 minuteAbstract Osteopenia, characterized by reduced bone mineral density (BMD), affects a significant proportion of aging American males, predisposing them to fractures and diminished quality of life. This orthopedic investigation evaluates the efficacy of AndroGel 1.62% testosterone gel in ameliorating bone health parameters in hypogonadal U.S. men aged 50-70 with osteopenia. Over 24 months, 150 participants received daily transdermal AndroGel or... Read more »
